Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis: Potential Implication in Progressive Disease Biology.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.

Brain and behavior·2026
Same author

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status.

Multiple sclerosis and related disorders·2026
Same journal

A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

VNN1 aggravates sepsis by promoting inflammation and oxidative stress through PPARγ signaling VNN1 in sepsis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Comparison between glioblastoma and brain metastases: How epigenetic remodeling can enhance immunotherapy.

Clinical immunology (Orlando, Fla.)·2026
Same journal

JAK-STAT3-MYC axis defines pathogenic stem cell-like memory CD4<sup>+</sup> T cells in rheumatoid arthritis.

Clinical immunology (Orlando, Fla.)·2026
Same journal

The baseline vaginal immune milieu is an important determinant of the inflammatory response induced by penile-vaginal sex.

Clinical immunology (Orlando, Fla.)·2026
Same journal

Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation.

Clinical immunology (Orlando, Fla.)·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Laquinimod in multiple sclerosis.

Paul S Giacomini1, Amit Bar-Or

  • 1Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Clinical Immunology (Orlando, Fla.)
|April 1, 2011
PubMed
Summary
This summary is machine-generated.

Laquinimod, an oral immune-modulator, shows promise for multiple sclerosis treatment. Clinical trials indicate efficacy on imaging markers with a good safety profile, potentially offering a new therapeutic option.

Related Experiment Videos

Last Updated: Jun 3, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Trials

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current treatments for relapsing-remitting MS focus on reducing inflammation and managing symptoms.
  • There is a need for novel therapies with improved efficacy and safety profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of laquinimod, an oral immune-modulatory molecule, in patients with relapsing-remitting multiple sclerosis.
  • To explore the potential mechanisms of action of laquinimod in preclinical models.

Main Methods:

  • Advanced phase clinical trials in relapsing-remitting multiple sclerosis.
  • Preclinical studies using animal models of MS to investigate laquinimod's effects on immune responses and CNS pathology.

Main Results:

  • Laquinimod demonstrated efficacy on imaging markers of disease activity in clinical trials.
  • Preclinical data suggest laquinimod modulates pro-inflammatory immune responses and cell trafficking.
  • Laquinimod may also exert neuroprotective effects within the central nervous system, limiting demyelination and axonal injury.
  • Favorable safety and tolerability profile observed in clinical studies.

Conclusions:

  • Laquinimod shows potential as a novel oral treatment for relapsing-remitting multiple sclerosis.
  • Further Phase III studies are needed to confirm clinical efficacy and safety.
  • If successful, laquinimod could offer a valuable new therapeutic option for MS patients.